|
1) Fletcher EC, DeBehnke RD, Lovoi MS, et al. Undiagnosed sleep apnea in patients with essential hypertension. Ann Intern Med. 1985; 103: 190-5
|
|
|
|
2) Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001; 19: 2271-7
|
|
|
|
|
3) Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000; 342: 1378-84
|
|
|
|
|
|
4) 日本高血圧学会高血圧治療ガイドライン作成委員会. 高血圧治療ガイドライン2009. 2009
|
|
|
|
|
|
5) Chobanian AV, Bakris GL, Black HR, et al, and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289: 2560-72
|
|
|
|
|
|
6) 循環器病の診断と治療に関するガイドライン(2008-2009年度合同研究班報告). 循環器領域における睡眠呼吸障害の診断・治療に関するガイドライン. Guidelines for Diagnosis and Treatment of Sleep Disordered Breathing in Cardiovascular Disease (JCS 2010) http://www.j-circ.or.jp/guideline/pdf/JCS2010,momomura.h.pdf)
|
|
|
|
|
|
7) Somers VK, Dyken ME, Clary MP, et al. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995; 964: 1897-904
|
|
|
|
|
|
8) Narkiewicz K, Somers VK. The sympathetic nervous system and obstructive sleep apnea: implications for hypertension. J Hypertens. 1997; 15(12 Pt 2): 1613-9
|
|
|
|
|
|
9) Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treat-ment with continuous positive airway pressure: an observational study. Lancet. 2005; 365: 1046-53
|
|
|
|
|
|
10) Buchner NJ, Sanner BM, Borgel J, et al. Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea redu-ces cardiovascular risk. Am J Respir Crit Care Med. 2007; 176: 1274-80
|
|
|
|
|
|
11) Engleman HM, Gough K, Martin SE, et al. Ambulatory blood pressure on and off continu-ous positive airway pressure therapy for the sleep apnea/hypopnea syndrome: effects in “non-dippers". Sleep. 1996; 19: 378-81
|
|
|
|
|
|
12) Dimsdale JE, Loredo JS, Profant J. Effect of continuous positive airway pressure on blood pressure: a placebo trial. Hypertension. 2000; 35: 144-7
|
|
|
|
|
|
13) Monasterio C, Vidal S, Durán J, et al. Effec-tiveness of continuous positive airway pressure in mild sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med. 2001; 164: 939-43
|
|
|
|
|
|
14) Pepperell JCT, Ramdassingh-Dow S, Crosthwaite N, et al. Ambulatory blood pressure after ther-apeutic and subtherapeutic nasal continuous posi-tive airway pressure for obstructive sleep ap-noea: a randomised parallel trial. Lancet. 2002; 359: 204-10
|
|
|
|
|
|
15) Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation. 2003; 107: 68-73
|
|
|
|
|
|
16) Mills PJ, Kennedy BP, Loredo JS, et al. Effects of nasal continuous positive airway pressure and oxygen supplementation on norepinephrine kinetics and cardiovascular responses in obstruc-tive sleep apnea. J Appl Physiol. 2006; 100: 343-8
|
|
|
|
|
|
17) Hui DS, To KW, Ko FW, et al. Nasal CPAP reduces systemic blood pressure in patients with obstructive sleep apnoea and mild sleepiness. Thorax. 2006; 61: 1083-90
|
|
|
|
|
|
18) Norman D, Loredo JS, Nelesen RA, et al. Effects of continuous positive airway pressure versus supplemental oxygen on 24-hour ambulatory blood pressure. Hypertension. 2006; 47: 840-5
|
|
|
|
|
|
19) Kohler M, Pepperell JC, Casadei B, et al. Continuous positive airway pressure and mea-sures of cardiovascular risk in men with OSAS. Eur Respir J. 2008; 32: 1488-96
|
|
|
|
|
|
20) Drager LF, Pedrosa RP, Diniz PM, et al. The effects of continuous positive airway pressure on prehypertension and masked hypertension in men with severe obstructive sleep apnea. Hypertension. 2011; 57: 549-55
|
|
|
|
|
|
21) Durán-Cantolla J, Aizpuru F, Montserrat JM, et al. Continuous positive airway pressure as treat-ment for systemic hypertension in people with obstructive sleep apnoea: randomised controlled trial. BMJ. 2010; 341: c5991
|
|
|
|
|
|
22) Robinson GV, Smith DM, Langford BA, et al. Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients. Eur Respir J. 2006; 27: 1229-35
|
|
|
|
|
|
23) Campos-Rodriguez F, Perez-Ronchel J, Grilo-Reina A, et al. Long-term effect of continuous positive airway pressure on BP in patients with hypertension and sleep apnea. Chest. 2007; 132: 1847-52
|
|
|
|
|
|
24) Barbé F, Durán-Cantolla J, Capote F, et al. Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea. Am J Respir Crit Care Med. 2010; 181: 718-26
|
|
|
|
|
|
25) Alajmi M, Mulgrew AT, Fox J, et al. Impact of continuous positive airway pressure therapy on blood pressure in patients with obstructive sleep apnea hypopnea: a meta-analysis of randomized controlled trials. Lung. 2007; 185: 67-72
|
|
|
|
|
|
26) Bazzano LA, Khan Z, Reynolds K, et al. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension. 2007; 50: 417-23
|
|
|
|
|
|
27) Haentjens P, Van Meerhaeghe A, Moscariello A, et al. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials. Arch Intern Med. 2007; 167: 757-64
|
|
|
|
|
|
28) Gotsopoulos H, Kelly JJ, Cistulli PA. Oral appliance therapy reduces blood pressure in obstructive sleep apnea: a randomized, controll-ed trial. Sleep. 2004; 27: 934-41
|
|
|
|
|
|
29) Otsuka R, Ribeiro de Almeida F, Lowe AA, et al. The effect of oral appliance therapy on blood pressure in patients withobstructive sleep apnea. Sleep Breath. 2006; 10: 29-36
|
|
|
|
|
|
30) Pépin JL, Tamisier R, Barone-Rochette G, et al. Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. Am J Respir Crit Care Med. 2010; 182: 954-60
|
|
|
|
|
|
31) Dohi T, Narui K, Kasai T, et al. Effects of olmesartan on blood pressure and insulin resist-ance in hypertensive patients with sleep-disor-dered breathing. Heart Vessels. 2011; 26: 603-8
|
|
|
|
|
|
32) Møller DS, Lind P, Strunge B, et al. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens. 2003; 16: 274-80
|
|
|
|
|
|
33) Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007; 131: 453-9
|
|
|
|
|
|
34) Gaddam K, Pimenta E, Thomas SJ. Spirono-lactone reduces severity of obstructive sleep apnea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010; 24: 532-7
|
|
|
|
|
|
35) Kraiczi H, Hedner J, Peker Y, et al. Comparison of atenolol, amlodipine, enalapril, hydrochloro-thiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea. Am J Respir Crit Care Med. 2000; 161: 1423-8
|
|
|
|
|
|
36) Zou D, Grote L, Eder DN, et al. A double-blind, crossover study of Doxazosin and Enalapril on peripheral vascular tone and nocturnal blood pressure in sleep apnea patients. Sleep Med. 2010; 11: 325-8
|
|
|
|
|
|
37) Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009; 373: 1275-81
|
|
|
|
|
|
38) Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011; 58: 559-65
|
|
|
|
|